

## **REMARKS**

Reconsideration and withdrawal of the rejections of the claimed invention is respectfully requested in view of the amendments, remarks and enclosures herewith, which place the application in condition for allowance.

### **I. STATUS OF CLAIMS AND FORMAL MATTERS**

Claims 15-18, 20-25 and 28-32 are pending in this application. No new matter has been added by this amendment.

It is submitted that the claims, herewith and as originally presented, are patentably distinct over the prior art cited in the Office Action, and that these claims were in full compliance with the requirements of 35 U.S.C. § 112. The amendments of the claims, as presented herein, are not made for purposes of patentability within the meaning of 35 U.S.C. §§§§ 101, 102, 103 or 112. Rather, these amendments and additions are made simply for clarification and to round out the scope of protection to which Applicants are entitled.

### **II. THE 35 U.S.C. 103(a) REJECTION HAS BEEN OVERCOME**

Claims 15-18, 20-25 and 28-32 were rejected as allegedly being obvious by Pappas-Fader et al. (US 5,736,486 -“Pappas-Fader”) and JP 10-330202.

While the applicants maintain the positions taken in their Appeal Brief which is incorporated here by reference, the applicants provide three additional points for consideration by the Examiner in order to clarify a few positions which have been lost during the course of prosecution (i.e. to date there have been eight (8) Office Actions on the merits and a restriction requirement while the applicants have only filed one RCE during prosecution).

#### ***Unexpected Results***

First, the applicants note that they have provided evidence of unexpected results for their combination of elements which constitute the claimed liquid formulation which has not been refuted by the Examiner. As the unexpected results appear to be clear cut to one of ordinary skill in the art, the applicants can only surmise that the Examiner was having difficulty reading the Tables within the specification.

These tables have been reformulated in the chart below (see next page) in order to address only the elected combination of sulfosuccinates and ALS inhibitors. The applicants have added a column entitled “Loss in %” and “Stable formulation?” to further illustrate the unexpected results.

	<b>RESULTS of Table 1</b>				<b>RESULTS of Table 2</b>	
Recipe No.	Ingredient	III	VIII	IX	1	2
Active Ingredients	<b>Iodosulfuron</b>	7.46	4.65	4.61	1.40	1.40
	Fenoxaprop-ethyl		7.94	8.01	11.08	11.08
	Mefenpyr-diethyl		3.05	3.08	4.17	4.17
Stabilizing polycarboxylic acids, e.g. <b>sulfosuccinates</b>	Triton GR 7 ME®	81.98	84.36		NONE	NONE
	Na-DOS			24.99		
Solvents	Propylene carbonate	10.56			83.35	73.35
	Edenor MESU®			39.52		
Surfactants	Soprophor CY8®			19.79		
	Genapol X-060®					10.0
The initial values and final values (g of iodosulfuron in the formulation were determined by HPLC)	Initial value (Iodosulfuron)	7.32	4.31	3.14	1.29	1.35
	Final value (Iodosulfuron), i.e. after storage at T = 54°C, 14 days	7.31	4.17	3.07	0.32	<0.05
	Loss in %	<b>0.1</b>	<b>3.2</b>	<b>2.2</b>	<b>75.2</b>	<b>&gt;96.3</b>
Comment	Stable formulation?	<b>YES</b>	<b>YES</b>	<b>YES</b>	<b>NO</b>	<b>NO</b>

As can be seen from the above data, the formulation of the invention resulted in stable formulations and much less loss of iodosulfuron compared with similar formulations lacking iodosulfuron.

### ***Restriction and Election of Species***

Since the restriction and election of species occurred long ago (10 October 2002), the applicants reiterate that the claims under examination are related to the species defined by claim 29 (component a) is sodium di-(2-ethylhexyl)sulfosuccinate) and the ALS inhibitor is iodosulfuron-methyl or its sodium salt), i.e. this elected combination was deemed by the Examiner as representing a patentably distinct species over other possible combinations within the scope of the applicants' originally filed claims.

As such, it is incongruous that a reference (Pappas-Faden) which is acknowledged to lack a proper teaching for the sulfosuccinate or ALS inhibitor, much less the specific combination elected can be an obvious variation of the applicants' claimed invention as examined when other variations have been held to be patentably distinct inventions.

***Credible explanation for teaching of solution as related to iodosulfuron in Pappen-Fader still has not been disclosed in the Office Action***

Pappen-Faden is still alleged to be directed to solutions as in the applicants' claimed invention, but there is no evidence for this assertion. The passage from col. 10, lines 24-44 from Pappen-Faden ("Useful formulations include liquids such as solutions... - col. 10, line 29) is relied upon in the Office Action, but this overlooks the fact that when considering the reference as a whole, it is clear that Pappen-Faden is directed toward herbicidal mixture of ***anilofos with propanil, or one or more of the compounds*** selected from azimsulfuron, metsulfuron methyl, chlorimuron ethyl, bensulfuron methyl, ethametsulfuron methyl, nicosulfuron, rimsulfuron, sulfometuron methyl, thifensulfuron methyl, tribenuron methyl, triflusulfuron methyl, methyl 2-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-6-(trifluoro-methyl)-3-pyridinecarboxylate, chlorsulfuron, and hexazinone. (see Abstract).

As there is no requirement that iodosulfuron (or any sulfuron-type herbicide) be present in the Pappen-Faden mixture, there is no evidence that the mention of solution by Pappen-Faden applies to an iodosulfuron mixture.

The Office Action cited col. 11, lines 9-29 as evidence of formation of a solution, but then overlooks the very next paragraph (see especially lines 30-35) in Pappen-Faden which contradicts that the reference to a solution in lines 9-29 applies to iodosulfuron:

"Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. Chemically stabilized aqueous sulfonylurea or agriculturally suitable ***sulfonylurea salt dispersions*** are taught in U.S. Pat. No. 4,936,900. Solution formulations of sulfonylureas with improved chemical stability are taught in U.S. Pat. No. 4,599,412 (this patent requires the contacting of the formulation with ***molecular sieves*** to achieve solution formulation)." One of ordinary skill in the art would glean from this paragraph that dispersions not solutions are intended or the use of molecular sieves would be required to achieve a solution with iodosulfuron.

With regard to the latter, one of ordinary skill in the art would not regard a composition which at best would require ***anilofos, iodosulfuron and molecular sieves*** to be an obvious variant of composition which only requires iodosulfuron and sodium di-(2-ethylhexyl)sulfosuccinate.

**CONCLUSION**

In view of the remarks and amendments herewith, the application is believed to be in condition for allowance. Favorable reconsideration of the application and prompt issuance of a Notice of Allowance are earnestly solicited. The undersigned looks forward to hearing favorably from the Examiner at an early date, and, the Examiner is invited to telephonically contact the undersigned to advance prosecution. The Commission is authorized to charge any fee occasioned by this paper, or credit any overpayment of such fees, to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By: /Howard C. Lee/  
Marilyn M. Brogan     Howard C. Lee  
Reg. No. 31,223         Reg. No. 48,104  
Telephone:     (212) 588-0800  
Facsimile:     (212) 588-0500

**United States Patent** [19]  
**Sandell**

[11] **Patent Number:** **4,599,412**  
[45] **Date of Patent:** **Jul. 8, 1986**

[54] **PROCESS FOR PREPARATION OF  
SULFONYLUREA SOLUTION  
FORMULATIONS**

[75] **Inventor:** **Lionel S. Sandell, Wilmington, Del.**

[73] **Assignee:** **E. I. Du Pont de Nemours and  
Company, Wilmington, Del.**

[21] **Appl. No.:** **714,508**

[22] **Filed:** **Mar. 21, 1985**

**Related U.S. Application Data**

[63] **Continuation-in-part of Ser. No. 554,787, Nov. 23,  
1983, abandoned.**

[51] **Int. Cl.<sup>4</sup> ..... C07D 251/41; C07D 251/46;  
C07D 239/69**

[52] **U.S. Cl. .... 544/211; 544/212;  
544/321; 544/320; 544/331; 544/332; 71/93;  
71/92; 260/96.5 R; 260/96.5 C**

[58] **Field of Search ..... 544/211, 212, 321, 320,  
544/331, 332; 71/93, 92; 260/96.5 R, 96.5 C**

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,127,405 11/1978 Levitt ..... 544/211  
4,169,719 10/1979 Levitt ..... 71/93

*Primary Examiner*—John M. Ford

[57] **ABSTRACT**

The process of making a solution formulation of a sulfonylurea compound which includes contacting the formulation with molecular sieves to provide improved chemical stability to the solution formulation.

**32 Claims, No Drawings**



(5) Processes of Preferred 4 wherein the solvent is N-methylpyrrolidone.

(6) Processes of Preferred 4 wherein the solvent is  $\gamma$ -butyrolactone.

(7) Processes of Preferred 4 wherein the solvent is triethyl phosphate.

(8) Processes of Preferred 4 wherein the molecular sieves are removed from the final formulation.

(9) Processes of Preferred 4 wherein M is lithium.

(10) Processes of Preferred 4 wherein the compound of Formula I is

2-[[[4-chloro-6-methoxypyrimidin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, ethyl ester, lithium salt;

2-[[[4,6-dimethylpyrimidin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester (sulfometuron methyl), lithium salt;

2-Chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron), lithium salt;

2-[[[4,6-dimethoxypyrimidin-2-yl)aminocarbonyl]aminosulfonylmethyl]benzoic acid, methyl ester, lithium salt;

N-[(4,6-dimethylpyrimidin-2-yl)aminocarbonyl]-2-hydroxybenzenesulfonamide, ethanesulfonate, lithium salt;

2-[[[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylaminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, lithium salt;

N'-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylaminocarbonyl]-N,N-dimethyl-1,2-benzenedisulfonamide, lithium salt; and

3-[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]-2-thiophenecarboxylic acid, methyl ester, lithium salt.

The formulations made by the process of this invention have improved chemical stability and are useful as pre-emergent and post-emergent herbicides.

## DETAILED DESCRIPTION OF THE INVENTION

### Synthesis

This invention relates to a novel process for the preparation of homogeneous solution formulations of sulfonylureas of Formula I with improved chemical stability, by contacting said solutions with molecular sieves.

Solution formulations are desirable because of the ease with which they can be measured, poured, handled or diluted in preparation for spraying. In addition, the processes and equipment necessary for preparing solution formulations are simpler and less costly than those needed for manufacturing dry formulations or dispersions. For example, the need for expensive grinding or drying equipment is obviated when preparing solution formulations.

In a true solution system, the compounds of Formula I are susceptible to the degradative effects of moisture and impurities present in at least trace quantities in all practical solvent systems. Hence the storage stability of these formulations may be a limiting factor in their usefulness over any period of time. Due to the high herbicidal activity of the compounds of Formula I, they may be required in only low concentrations in a formulation. In this case, the stability problem may be aggra-

vated because of the increased relative concentration of the contaminants which promote decomposition.

The sulfonylureas of Formula I can be prepared by methods known in the art; for example, see U.S. Pat. No. 4,127,405, U.S. Pat. No. 4,394,506 and U.S. Pat. No. 4,383,113, the disclosures of which are hereby incorporated by reference.

Agriculturally suitable compounds of Formula I can be prepared by a number of ways known to the art. For example, the compounds of Formula I can be made by treating the corresponding N-protonated sulfonylureas with a solution of an alkali or alkaline earth metal salt having a sufficiently basic anion (e.g., hydroxide, alkoxide, carbonate or hydride). Ammonium and quaternary amine salts can be made by similar techniques.

The compounds of Formula I can also be prepared by exchange of one cation for another. Cationic exchange can be effected by direct treatment of an aqueous solution of a salt of Formula I (e.g., an alkali metal or quaternary amine salt) with a solution containing the cation to be exchanged. This method is most effective when the desired compound of Formula I containing the exchanged cation is insoluble in water and can be separated by filtration.

Exchange may also be effected by passing an aqueous solution of a salt of a compound of Formula I (e.g., an alkali metal or quaternary amine salt) through a column packed with a cation exchange resin containing the cation to be exchanged. In this method the cation of the resin is exchanged for that of the original salt and the desired product is eluted from the column. This method is particularly useful when the desired salt is water-soluble.

It has been found that solution formulations of compounds of Formula I can be prepared with improved chemical stability of contacting said solution formulations with molecular sieves.

Molecular sieves are synthetically produced crystalline metal aluminosilicates, that have been activated for adsorption by removing their water of hydration.

In contrast to other adsorbents, the pores of any particular type of molecular sieve are precisely uniform in size and of molecular dimensions. Depending on the size of these pores, molecules may be readily adsorbed, slowly adsorbed or completely excluded. This sieve-like selectivity based on molecule size, plus a selective preference for polar or polarizable molecules give molecular sieves a high level of adsorption efficiency.

In the process of this invention, the sulfonylurea of Formula I is dissolved in a suitable nonreactive solvent which allows for a concentration of at least 0.5 weight percent. The maximum allowable concentration will vary from formulation to formulation and is limited only by the solubility of the specific active ingredient in the specific solvent employed.

The solution formulation may then be permanently stored over molecular sieves. Alternatively, the formulation may be passed through a column packed with molecular sieves. In the preferred process, the solution formulation is stirred with molecular sieves for at least several minutes, preferably for at least one hour, and is

then separated from the sieves. The exact time of contact is not critical but does depend, in part, upon the quantity of molecular sieves employed; the use of larger quantities allows shorter contact times while lesser quantities require longer contact time. As is well known to one skilled in the art, molecular sieves are generally used in quantities significantly in excess of the amount required to achieve a specific result. In the process of this invention, it is likewise desirable to employ quantities of sieves in excess of that amount actually required to achieve stabilization.

Preferred molecular sieves are the types 3A, 4A and 5A with nominal pore diameters of 3 Å, 4 Å and 5 Å, respectively. Molecular sieves with larger pore diameters (e.g., type 13X) may adsorb the active ingredient or solvent molecules themselves.

In the compounds of Formula I, a wide variety of cations, M, is permissible. Preferred cations are ammonium, substituted ammonium, alkali or alkaline earth metals. More preferred are compounds of Formula I where the cation is lithium.

The non-reactive solvents of this invention are aprotic and include, but are not limited to, cyclohexanone, anisole, acetophenone, benzonitrile, acetonitrile, acetone, methyl ethyl ketone, isophorone, mesityl oxide, ethyl acetate, dichloromethane monochlorobenzene, benzaldehyde, tetrahydrofuran, ethylene dichloride, and 1,1,1-trichloroethane.

Solvents of the dipolar aprotic class, typically with dielectric constants of about 20 or more, are preferred because of their greater solubilizing power for the compounds of Formula I. Examples are nitroethane, triethyl phosphate,  $\gamma$ -butyrolactone, propylene carbonate, dimethylsulfoxide, dimethylacetamide, dimethylformamide, and N-methyl-pyrrolidone. N-methyl-pyrrolidone, triethyl phosphate,  $\gamma$ -butyrolactone and propylene carbonate are most preferred because of their low toxicity, good solubilizing power and good chemical stabilization of the active ingredient.

The solution formulation may optionally contain dissolved surfactants at concentrations ranging from about 0.1 to 60 weight %. The higher ratios of surfactant to active ingredient are sometimes desirable and can be achieved by incorporation into the formulation or by tank mixing. Among the useful surfactants used in these compositions are common nonionic wetting agents such as the polyoxyethylene alcohols, nonyl phenols, esters, diesters, and sorbitol esters, and polyoxyethylene-polyoxypropylene block copolymers.

Anionic surfactants useful in these compositions include for example, alkyl naphthalenesulfonates, alkyl benzenesulfonates, dialkylsulfosuccinates, polyoxyethylene alkylsulfosuccinates and phosphates and their salts (e.g., sodium and ammonium).

The solution formulations of this invention may be used in combination with known herbicides. Such known herbicides may be added to the solution formulation in desired amounts prior to the step of contacting the solution formulation with the molecular sieves so long as this does not interfere with chemical stability.

In the following examples, all parts are by weight unless otherwise indicated. Molecular sieves were man-

ufactured by the Davison Chemical Division of W. R. Grace Co.; however, sieves from other manufacturers would also be suitable.

#### EXAMPLE 1

This example illustrates the effect of storing a solution of the sodium salt of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron) in N-methylpyrrolidone over type 4A sieves.

2-Chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide, sodium salt: 5.0%

N-methylpyrrolidone: 95.0%

The sodium salt of the title compound was dissolved in the N-methylpyrrolidone using a magnetic stirrer in a flask. The solution was split into four portions of about 7 gm each.

About 2 gm of type 4A sieves were added to two of the portions in glass vials and sealed. One portion was stored in a freezer ( $-6^{\circ}\text{C.}$ ) and the other in a  $45^{\circ}\text{C.}$  oven for 15 days. The cold storage and oven aged samples were then analyzed for active ingredient by high performance liquid chromatography.

The % Relative Decomposition after oven aging was calculated as:

$$\left( \frac{\% \text{ Active}_{\text{freezer}} - \% \text{ Active}_{45^{\circ}\text{C.}}}{\% \text{ Active}_{\text{freezer}}} \right) \times 100\%.$$

The results were compared to those obtained in the two unstabilized portions, containing no molecular sieves.

Type of Treatment	% Active		% Relative Decomposition
	Freezer	$45^{\circ}\text{C.}$	
Stabilized with sieves	4.19	4.08	2.6
Unstabilized (no sieves)	4.19	3.87	7.6

The portions containing molecular sieves had better chemical stability than the unstabilized portions of the solution.

#### EXAMPLE 2

This example illustrates the effect of storing a solution of the sodium salt of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron) in  $\gamma$ -butyrolactone over type 4A sieves.

2-Chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide, sodium salt: 5%

$\gamma$ -Butyrolactone: 95%

The procedure of Example 1 was followed except that the solvent was  $\gamma$ -butyrolactone.

Type of Treatment	% Active		% Relative Decomposition after 15 days
	Freezer	$45^{\circ}\text{C.}$	
Stabilized with sieves	4.15	3.96	4.6

-continued

Type of Treatment	% Active		% Relative Decomposition after 15 days
	Freezer	45° C.	
Unstabilized (no sieves)	4.20	3.93	6.4

## EXAMPLE 3

This example illustrates the effect of storing a solution of the sodium salt of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron) in N-methylpyrrolidone containing a dissolved surfactant, Brij ®78 (20 POE stearyl alcohol) over type 4A molecular sieves (POE=polyoxyethylene).

2-Chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide, sodium salt: 5.0%

Brij ®78: 25.0%

N-methylpyrrolidone: 70.0%

The procedure of Example 1 was followed except that the Brij ®78 was dissolved in the N-methylpyrrolidone, followed by the sodium salt of the title compound.

Type of Treatment	% Active		% Relative Decomposition after 14 days
	Freezer	45° C.	
Stabilized with sieves	4.27	4.04	5.4
Unstabilized (no sieves)	4.27	3.69	13.6

## EXAMPLE 4

This example illustrates the effect of treating a solution of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron), sodium salt in N-methylpyrrolidone, containing a dissolved surfactant, Brij ®96, (10 POE-oleyl alcohol) with Type 4A and 5A sieves, then removing the sieves.

2-Chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide, sodium salt: 2.3%

Brij ®96: 24.0%

N-methylpyrrolidone: 73.7%

The Brij ®96 was dissolved in the N-methylpyrrolidone, followed by the title compound, using magnetic stirring in a stoppered Erlenmeyer flask. After solution was complete, 14 gm of type 4A sieves were added to a 70 gm portion of solution, and 14 gm of type 5A sieves was added to another 70 gm portion of the solution. The solutions were slowly stirred with the molecular sieves in stoppered flasks for 2 hours. The sieves were then separated from the formulations by filtration under a nitrogen blanket. Portions of the sieve treated solutions were stored at 45° C. for 3 weeks, after which time they were analyzed for active ingredient. The results were compared to those of untreated solutions stored in a refrigerator (5° C.) and at 45° C.

Type of Treatment	% Active		% Relative Decomposition vs. Untreated Refrigerator Control
	Refrigerator	45° C.	
Untreated Control	2.08	1.34	35.6
Stirred with 4A sieves	—	1.92	7.7
Stirred with 5A sieves	—	1.91	8.2

The sieve treated solution formulations showed much better chemical stability than the untreated portions of the formulation.

## EXAMPLE 5

This example is similar to Example 4, except that the surfactant was Brij ®98 (20 POE-oleyl alcohol) instead of Brij ®96.

Type of Treatment	% Active		% Relative Decomposition vs. Untreated Refrigerator Control after 22 days
	Refrigerator	45° C.	
Untreated Control	2.10	1.35	35.7
Stirred with 4A sieves	—	1.87	11.0
Stirred with 5A sieves	—	1.93	8.1

## EXAMPLE 6

This example illustrates the effect of treating a high concentration of 2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, sodium salt in N-methylpyrrolidone with type 4A molecular sieves, then removing the sieves.

2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, sodium salt: 35%

N-methylpyrrolidone: 65%

17.5 gm of the title compound was dissolved in 32.5 gm of N-methylpyrrolidone in a stoppered Erlenmeyer flask. 10 gm of Type 4A sieves were added and the solution was stirred gently with the sieves for 2 hours. The solution was then filtered to remove the sieves, and portions were stored in the refrigerator and at 45° C. for 18 days.

Another solution was prepared as above, but was not treated with molecular sieves. Portions of this solution were stored in the refrigerator and at 45° C. for 23 days. Because of the different storage times for the treated and untreated solutions, stability comparisons in the following table are made on the basis of % relative decomposition per day (i.e., % relative decomposition divided by time in storage).

Type of Treatment	% Active		% Relative Decomposition per day vs. Control
	Refrigerator	45° C.	
Untreated Control	30.62	17.32	1.89

-continued

Type of Treatment	% Active		% Relative Decomposition per day vs. Control
	Refrigerator	45° C.	
Sieve treated	30.88	27.36	0.63

The sieve-treated high active solution formulation of 2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, sodium salt had substantially better chemical stability than the untreated control solution.

## EXAMPLE 7

This example illustrates the effect of treating a solution of 2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, ammonium salt in propylene carbonate, with type 4A and 5A molecular sieves.

2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, ammonium salt: 10.0%

Propylene carbonate 90.0%

35 gm portions of the above solution were stirred with 7 gm of type 4A and 5A sieves for 2 hours in stoppered flasks. The treated solutions were separated from the sieves by filtration under a nitrogen atmosphere. Portions of the sieve-treated solutions were stored at 45° C. for 22 days, after which time they were analyzed for active ingredient. The results were compared to those of untreated controls stored at -6° C. and at 45° C.

Type of Treatment	% Active		% Relative Decomposition vs. Untreated Freezer Control
	Freezer	45° C.	
Untreated Control	8.60	0.62	93
Stirred with 4A sieves	—	1.42	84
Stirred with 5A sieves	—	1.55	82

## EXAMPLE 8

This example illustrates the in situ preparation of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-aminocarbonyl]benzenesulfonamide (chlorsulfuron), lithium salt, by reaction of the sulfonylurea with lithium carbonate in N-methylpyrrolidone followed by treatment of the solution with type 4A molecular sieves to stabilize the formulation. 36.81 gm of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide (chlorsulfuron) was dissolved in 78.73 gm of N-methylpyrrolidone. 44.6 gm of lithium carbonate was added and the mixture was stirred for 45 minutes in an open Erlenmeyer flask. During this period, gas bubbles were generated due to the evolution of carbon dioxide from the reaction of the carbonate with the sulfonylurea. The solution was then filtered to remove undissolved lithium carbonate. Approximately one-half (65 gm) of the filtered solution was stirred gently with 30 gm of type 4A sieves (previously acti-

vated at 300° C. overnight) for 4 hours. The sieves were then removed by filtration under a nitrogen blanket. A portion of the sieve-treated solution was stored at 45° C. for 3 weeks after which time it was analyzed for active ingredient. The results were compared to those of untreated controls stored at 5° C. and 45° C.

Type of Treatment	% Active		% Relative Decomposition vs. Untreated Refrigerator Control
	Refrigerator	45° C.	
Untreated Control	30.47	27.70	9.1
Stirred with 4A sieves	—	30.18	0.95

Molecular sieve treatment thus substantially improved the chemical stability of the solution formulation of 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-aminocarbonyl]benzenesulfonamide (chlorsulfuron), lithium salt.

## EXAMPLE 9

This example illustrates the in-situ preparation of 2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, lithium salt, by reaction of the sulfonylurea with lithium hydroxide in N-methylpyrrolidone, followed by treatment of the solution with type 5A molecular sieves to stabilize the formulation.

41.29 gm of 2-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester was dispersed in 76.22 gm of N-methylpyrrolidone in a stoppered Erlenmeyer flask. 2.49 gm of anhydrous lithium hydroxide was added and the mixture was allowed to stir overnight. After 24 hours of stirring, an additional 0.25 gm of anhydrous lithium hydroxide was added and stirred for approximately two more hours. Undissolved solids were then separated from the solution by centrifugation. Approximately half (60 gm) of the clarified solution was stirred gently with 30 gm of type 5A sieves (previously activated overnight at 300° C.) for 4 hours. The sieves were then removed by filtration under a nitrogen blanket.

A portion of the sieve-treated solution was stored at 45° C. for 3 weeks, after which time it was analyzed for active ingredient. The results were compared to those of untreated control stored at 5° C. and 45° C.


Type of Treatment	% Active		% Relative Decomposition vs. Untreated Refrigerator Control
	Refrigerator	45° C.	
Untreated Control	34.4	29.6	14.0
Stirred with 5A sieves	—	32.4	5.8

The sieve treatment improved the chemical stability of the solution formulation of 2-[N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester lithium salt.


What is claimed is:

11


1. A process for stabilizing a solution formulation comprising a compound of Formula I dissolved in an aprotic solvent, which is subject to the degradative effects of moisture and impurities:




wherein  
R is



R<sub>1</sub> is H or CH<sub>3</sub>;  
R<sub>2</sub> is F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> alkyl, SO<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>, S(O)<sub>n</sub>R<sub>8</sub>, SO<sub>2</sub>NCH<sub>3</sub>(OCH<sub>3</sub>), CO<sub>2</sub>R<sub>9</sub>, OSO<sub>2</sub>R<sub>10</sub>,



R<sub>3</sub> is H, F, Cl, Br, CH<sub>3</sub>, OCH<sub>3</sub> or CF<sub>3</sub>;  
R<sub>4</sub> is Cl, NO<sub>2</sub> or CO<sub>2</sub>R<sub>10</sub>;  
R<sub>5</sub> is Cl, Br, SO<sub>2</sub>NR<sub>6</sub>R<sub>7</sub>, S(O)<sub>n</sub>R<sub>10</sub> or CO<sub>2</sub>R<sub>10</sub>;  
R<sub>6</sub> and R<sub>7</sub> are independently C<sub>1</sub>-C<sub>3</sub> alkyl;  
R<sub>8</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl or C<sub>1</sub>-C<sub>3</sub> alkyl substituted by 1-5 atoms of F, Cl or Br;  
R<sub>9</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>Cl or CH<sub>2</sub>CH=CH<sub>2</sub>;  
R<sub>10</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl;  
R<sub>11</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, CH<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>C≡CH or C<sub>1</sub>-C<sub>3</sub> alkyl substituted with 1-5 atoms of F, Cl or Br;  
n is 0 or 2;  
M is an agriculturally suitable cation;  
m is 1, 2 or 3;  
Z is CH or N;  
X is CH<sub>3</sub>, OCH<sub>3</sub>, Cl or OCHF<sub>2</sub>; and  
Y is CH<sub>3</sub>, OCH<sub>3</sub>, CH(OCH<sub>3</sub>)<sub>2</sub>, OCHF<sub>2</sub>



provided that when


X is Cl, then Z is CH and Y is OCH<sub>3</sub>, or OCF<sub>2</sub>H; said process comprising contacting under adsorption conditions said solution formulation with molecular sieves having nominal pore diameters sized to adsorb water and to exclude the solvent and compound of

12


Formula I, for a sufficient time to impart enhanced chemical stability to said solution formulation.

2. The process of claim 1 wherein M is an ammonium, substituted ammonium, alkali or alkaline earth metal ion.

3. The process of claim 2 wherein R is



15



20

R<sub>2</sub> is Cl, CH<sub>3</sub>, SO<sub>2</sub>N(CH<sub>3</sub>)<sub>2</sub>, S(O)<sub>n</sub>R<sub>8</sub>, CO<sub>2</sub>R<sub>9</sub>, OSO<sub>2</sub>R<sub>10</sub>, OR<sub>11</sub> or NO<sub>2</sub>;  
R<sub>3</sub> is H, Cl, CH<sub>3</sub>, OCH<sub>3</sub> or CF<sub>3</sub>;  
R<sub>8</sub> is C<sub>1</sub>-C<sub>3</sub> alkyl, CF<sub>3</sub>, CF<sub>2</sub>H or CF<sub>2</sub>CF<sub>2</sub>H;  
R<sub>9</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl; and  
R<sub>11</sub> is C<sub>1</sub>-C<sub>4</sub> alkyl, CF<sub>3</sub>, CF<sub>2</sub>H or CF<sub>2</sub>CF<sub>2</sub>H.

4. The process of claim 3 wherein said molecular sieves are crystalline metal aluminosilicates activated for adsorption by removing their water of hydration and which have a pore size of 3-5 Å.

5. The process of claim 4 wherein said solvent is a dipolar aprotic solvent.

6. The process of claim 5 wherein said dipolar aprotic solvent is selected from the group consisting of N-methylpyrrolidone, γ-butyrolactone, and triethyl phosphate.

7. The process of claim 6 wherein M is lithium.

8. The process of claim 7 wherein said compound of Formula I is 2-[[[4-chloro-6-methoxypyrimidin-2-yl]aminocarbonyl]aminosulfonyl]benzoic acid, ethyl ester, lithium salt.

9. The process of claim 7 wherein said compound of Formula I is 2-[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl]aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, lithium salt.

10. The process of claim 7 wherein said compound of Formula I is 2-[[[4,6-dimethylpyrimidin-2-yl]aminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, lithium salt.

11. The process of claim 7 wherein said compound of Formula I is 2-chloro-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]benzenesulfonamide, lithium salt.

12. The process of claim 7 wherein said compound of Formula I is 2-[[[4,6-dimethoxypyrimidin-2-yl]aminocarbonyl]aminosulfonylmethyl]benzoic acid, methyl ester, lithium salt.

13. The process of claim 7 wherein said compound of Formula I is N-[(4,6-dimethylpyrimidin-2-yl)aminocarbonyl]-2-hydroxybenzenesulfonamide, ethanesulfonate, lithium salt.

14. The process of claim 7 wherein said compound of Formula I is 2-[[[4-methoxy-6-methyl-1,3,5-triazin-2-

## 13

yl)-N-methylaminocarbonyl]aminosulfonyl]benzoic acid, methyl ester, lithium salt.

15. The process of claim 7 wherein said compound of Formula I is N'-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylaminocarbonyl]-N,N-dimethyl-1,2-benzenedisulfonamide, lithium salt.

16. The process of claim 7 wherein said compound of Formula I is 3-[[[4-methoxy-6-methyl-1,3,5-triazin-2-yl)aminocarbonyl]aminosulfonyl]-2-thiophenecarboxylic acid, methyl ester, lithium salt.

17. The stabilized formulation made by the process of claim 1.

18. The stabilized formulation made by the process of claim 2.

19. The stabilized formulation made by the process of claim 3.

20. The stabilized formulation made by the process of claim 4.

21. The stabilized formulation made by the process of claim 5.

## 14

22. The stabilized formulation made by the process of claim 6.

23. The stabilized formulation made by the process of claim 7.

24. The stabilized formulation made by the process of claim 8.

25. The stabilized formulation made by the process of claim 9.

26. The stabilized formulation made by the process of claim 10.

27. The stabilized formulation made by the process of claim 11.

28. The stabilized formulation made by the process of claim 12.

29. The stabilized formulation made by the process of claim 13.

30. The stabilized formulation made by the process of claim 14.

31. The stabilized formulation made by the process of claim 15.

32. The stabilized formulation made by the process of claim 16.

\* \* \* \* \*

30

35

40

45

50

55

60

65